Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Feb;282(2):691-699.
doi: 10.1007/s00405-024-08949-7. Epub 2024 Sep 13.

Biologics for eosinophilic otitis media: a retrospective case study in a multidisciplinary center

M Czajkowski  1 , S Machiels  2 , C Leclercq  1 , A L Poirrier  1 , F Schleich  3 , R Louis  3 , B Dezfoulian  4 , P Lefebvre  1 , V Defaweux  5 , S Camby  1 , F Rogister  6
Affiliations
Case Reports

Biologics for eosinophilic otitis media: a retrospective case study in a multidisciplinary center

M Czajkowski et al. Eur Arch Otorhinolaryngol. 2025 Feb.

Abstract

Purpose: Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media characterized by eosinophilic accumulation in the middle ear mucosa and effusion. It is refractory to conventional treatments and is strongly associated with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The diagnostic criteria for EOM were established by IINO in 2011. With the recognition of type 2 inflammatory diseases, the gold standard of treatment is the systemic and topical administration of corticosteroids. Recently, several retrospective studies have demonstrated the efficacy of biologic treatments in EOM. We aimed to share our experience regarding the response of EOM after the use of biologics.

Methods: This is a retrospective observational analysis including patients with refractory EOM treated with different biologics (benralizumab, omalizumab, mepolizumab, dupilumab) for concomitant severe asthma, urticaria and/or severe uncontrolled CRSwNP from 2011 to 2023. Treatment effectiveness in terms of EOM severity was measured using medical Global Evaluation of Treatment Effectiveness (GETE).

Results: We illustrated 4 clinical cases of uncontrolled comorbid EOM and demonstrated the complexity of multidisciplinary medical pathway with good response to biologics. We also observed that response to EOM and CRSwNP does not always follow that of asthma.

Conclusions: The results of our small sample were consistent with those found in the literature and showed control of EOM with biologics. We need a larger multicentric sample and methodology to confirm these results and to compare the efficacy of different biologics.

Keywords: Asthma; Biologics; CRSwNP; Otitis media; Type 2 inflammatory disease; Urticaria.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: No funding was received to assist with the preparation of this manuscript.

References

    1. Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M (2011) Diagnostic criteria for eosinophilic otitis media, a newly recognised middle ear disease. Auris Nasus Larynx 38:456–461 - DOI - PubMed
    1. Tomioka S, Kobayashi T, Takasaka T (1997) Intractable Otitis Media in patients with bronchial asthma (Eosinophilic Ottis Media). In: Sanna M (ed) Cholesteatoma and mastoid surgery. CICI Edizioni International, Rome, pp 851–853
    1. Iino Y (2023) Eosinophilic otitis media; state-of-the-art diagnosis and treatment. Auris Nasus Larynx 50(4):479–489. https://doi.org/10.1016/j.anl.2022.11.004 - DOI - PubMed
    1. Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P (2012) Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN European survey. Allergy 67(1):91–98. https://doi.org/10.1111/j.1398-9995.2011.02709.x - DOI - PubMed
    1. Ryu G, Kim DW (2020) Th2 inflammatory responses in the development of nasal polyps and chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. ;20(1):1–8. https://doi.org/10.1097/ACI.0000000000000588 . PMID: 31567293

MeSH terms

LinkOut - more resources